Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?

There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in...

Full description

Saved in:
Bibliographic Details
Published in:Experimental Oncology
Date:2012
Main Authors: Naumnik, W., Naumnik, B., Niewiarowska, K., Ossolinska, M., Chyczewska, E.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2012
Subjects:
Online Access:https://nasplib.isofts.kiev.ua/handle/123456789/139877
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Cite this:Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-139877
record_format dspace
spelling Naumnik, W.
Naumnik, B.
Niewiarowska, K.
Ossolinska, M.
Chyczewska, E.
2018-06-21T12:58:45Z
2018-06-21T12:58:45Z
2012
Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/139877
There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before chemotherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are significantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A negative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies.
We are indebted to Robert Mroz for his help with the ELISA equipment. This work was granted by Polish Ministry of Science and Higher Education (NN 401 230134; 2301/B/P01/2008/34).
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
spellingShingle Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
Naumnik, W.
Naumnik, B.
Niewiarowska, K.
Ossolinska, M.
Chyczewska, E.
Original contributions
title_short Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_full Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_fullStr Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_full_unstemmed Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_sort novel cytokines: il-27, il-29, il-31 and il-33. can they be useful in clinical practice at the time diagnosis of lung cancer?
author Naumnik, W.
Naumnik, B.
Niewiarowska, K.
Ossolinska, M.
Chyczewska, E.
author_facet Naumnik, W.
Naumnik, B.
Niewiarowska, K.
Ossolinska, M.
Chyczewska, E.
topic Original contributions
topic_facet Original contributions
publishDate 2012
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before chemotherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are significantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A negative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/139877
citation_txt Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ.
work_keys_str_mv AT naumnikw novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT naumnikb novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT niewiarowskak novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT ossolinskam novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT chyczewskae novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
first_indexed 2025-11-30T15:30:01Z
last_indexed 2025-11-30T15:30:01Z
_version_ 1850857972285046784